an expanding healthtech ecosystem -...

#3

Special magazine Medica 2017

An expanding HealthTech ecosystem

Minimally invasive technologies

Connected health

Biomaterials

Medical imagingMedical plastics

Implants

Medical textiles

© iS

tock

pho

tos

To mark the Medica 2017 exhibition, Michel PLANTEVIN, President of i-Care Cluster Health Technology Auvergne-Rhône-Alpes, answers our questions.

Michel Plantevin, you are taking over the presidency of i-Care Cluster from Emmanuel Blanc: who are you and what is your vision for the cluster?

Michel Plantevin - I have been involved in the cluster for three years as a member and as an officer on behalf of the

company I run, Solware Life, a software company in the healthcare sector. During that time I have been able to evaluate the benefits of contributing to the development of the regional health technology ecosystem. The work of my predecessor and his teams has borne fruit: we now have 120 members and i-Care has reinforced its position in the regional health ecosys-tem in recent years. This momentum must not weaken, because digital is an essential subject in all activity sectors, including health technology. As a player in the young digital economy and an IT publisher with an international presence, I fully intend to contribute my experience and bring a new eye to the subject: the i-Care Cluster must be at the heart of the digital trans-formation of health organisations and practices.

From the region to Europe and beyond… this is your priority goal, but what levers can you use to achieve it?

MP - Our region is France’s second biggest economy, the fourth in medical and health tech-nology and the eighth in Europe… not to mention that 25% of France’s medical equipment industry is based in Auvergne-Rhône-Alpes. The first lever we can use thus has considerable legitimacy - the region’s economic importance. The second has equal weight, and consists of the excellence of our sector. Two strengths to boost our international reach - let’s activate them. As the former chair of Four Motors for Europe, created twenty years ago by the regions of Rhône-Alpes, Lombardy, Catalonia and Baden-Württemberg, the region organised a wor-king mission to Scandinavia in September, where I represented the i-Care Cluster alongside representatives of life science clusters from the three other regions. The goal? To meet in-novative players in the life sciences from northern Europe. This mission is an example of a powerful lever, shining a spotlight on all the skills of our region, presenting opportunities for partnerships and chances to create exchanges of intelligence and stimulate activity. Attentive to the operation of Danish and Swedish clusters, which are very innovative in terms of orga-nisation, governance and added-value services for their members, i-Care has forged links to gradually create a kind of Europe-wide mesh that will be beneficial for all. Other levers, such as organising Techdays in the region and attending the Entretiens Jacques Cartier in Montreal (Canada) and the Medica exhibition in Düsseldorf (Germany), also help to consolidate the reputations of our companies in Europe and gain international visibility.

The international Medica 2017 show: is this a high point for the i-Care Cluster?

MP - It is one of the highlights of the year, because we organize attendance at the exhibition for the companies and partners concerned. But as I said, this international event is part of a global support strategy aiming to boost the activity of our companies. And to serve our members better and improve further, we must develop new added-value initiatives for our members, such as open innovation and experimentation through use (Living Lab), and evolve our methods of operation to give the cluster’s economic model a long-term future like the Scandinavian clusters have done. In the immediate future, the companies and start-ups exhi-biting at the collective stand organised by the i-Care Cluster have a strong hand: I wish them all a great exhibition!

Michel Plantevin, President of the i-Care Cluster

HEALTH TECHNOLOGY AUVERGNE-RHÔNE-ALPES CLUSTER

2 i-Care mag #3 / Health Technology in Auvergne-Rhône-Alpes

Contents

2 / Editorial by Michel Plantevin

3 / Auvergne-Rhône-Alpes An area for new opportunities

4 / LyonBiopôle The gateway to healthcare innovation

6 / Edap TMS Therapeutic ultrasound

7 / Texinov Medical textiles

9 / BioparHom Connected health

10 / NeoMedLight Medical devices

11 / Rhizom Connected health

12 / Setmi Medical devices

13 / ADERLY Economic Development Agency

14 / AEPI & Grenoble Alpes Métropole Economic Development Agency

15 / Medi’Nov Connection 2018

This magazine is published by the i-Care Cluster Managing editor: Gérald Comtet

Design & production: artenium, Laurent Annino, Camille Guy Copywriter: Hervé Heurteau2 rue des Mûriers - Villa Créatis 69009 Lyon - France www.artenium.com

Auvergne-Rhône-Alpesan area for new opportunities

Le Puy-en-Velay

Aurillac

Clermont-Ferrand

Moulins

Valence

Privas

Saint-Etienne

LyonLOIRE

RHÔNEAIN

ISÈRE

DRÔME

ARDÈCHE

PUY-DE-DÔME

HAUTE-LOIRECANTAL

ALLIER

SAVOIE

HAUTE-SAVOIEBourg-en-Bresse

Annecy

Chambery

Grenoble

7.8 Mresidents

Europeancrossroads

€240bn

GDP

13 %of the French territory

1st French industrial region

Research & development2.71% GDP(2.69% GDP for North America)

3i-Care mag #3 / Health Technology in Auvergne-Rhône-Alpes

The gateway to healthcare innovation


Auvergne R hône Alpes- -


BOOST your business in Europe

INNOVATE in a dynamic ecosystem

213 R&D PROJECTS FUNDEDsince 2005

€992 M of total investment€406 M public funding

+ €708 M OF PRIVATE MONEY RAISED BY LYONBIOPOLE MEMBERSsince 2013

w w w . l y o n b i o p o l e . c o m

GO GLOBAL & access new markets105 COMPANIES SUPPORTEDIN 7 MISSIONSaround the world in 2016

HOST your company in BSL2 & BSL3 laboratories

& GMP/GLP facilities26 ORGANIZATIONS HOSTED

in 2016

200 MEMBERS> 4 WORLD CLASS LEADERS

> 180 INNOVATIVE COMPANIES> 16 RESEARCH & CLINICAL CENTERS

GATHERED THROUGH 95 EVENTS PER YEAR, (CO)-ORGANIZED BY LYONBIOPOLE

Lyonbiopole’s founders











in 2016















in 2016





Discover4 Start-ups


Discover2 COMPANIES



Revenue: €35.6 B, 73% from exports

16 R&D engineers

6 subsidiaries (USA, Japan, South Korea, Malaysia, Italy, Germany)

2 offices in Dubai and Moscow

180 patents registered

(114 granted)

12% of revenue devoted to R&D

You rely on local players to develop your activity: is this a key element of your success?Ever since its foundation, EDAP TMS has exploited the richness of the regional eco-nomic fabric and its expertise in the medi-cal and healthcare field. By involving the best specialists in basic research (INSERM) and clinical research (CHU Édouard Her-riot and Léon Bérard, the HCL) and wor-king with the best-performing suppliers and manufacturers to develop its projects, EDAP TMS has made rapid progress. At the same time, our teams have contributed to the regional dynamic by getting invol-ved with the region’s competitive clusters and skills hubs. The vitality of the local economic ecosystem is definitely one of the keys to our success.At the heart of your development is R&D: how does EDAP TMS contribute to the effectiveness of diagnoses and treatments, and ultimately to improving patient comfort?We involve our partners in the medi-cal sector and innovative manufacturers in our product design process from the very beginning. We save valuable time by conducting the necessary research and clinical studies, the development of inno-vative technologies such as high-tech MRI imaging and the completion of the legal

accreditation all at the same time. This is how we help improve patients’ treatment pathways in our field of therapeutic in-tervention, prostate cancer and urinary stones: better diagnostic performance, extremely precise treatment, reduced in-vasiveness, greater clinical effectiveness (low morbidity) – and thus improved pa-tient comfort and better quality of life!You already export your equipment: what do you hope to gain from Medica 2017?We export a large proportion of our pro-duction throughout Europe and the world. Our HIFU equipment (Ablatherm® HIFU and Ablatherm® Fusion, an evolution of Ablatherm® HIFU incorporating the mer-ging of diagnostic images) is exported to the USA. Focal One, the latest generation of HIFU device dedicated to focal therapy for prostate cancer, is currently under-going FDA approval to be exported there soon as well. Medica is an opportunity to demonstrate our expertise, but beyond this purely tech-nological aspect it is also a valuable oppor-tunity to make new contacts. Distributors and basic research partners, designers and manufacturers of high-tech medical systems and components… all are able to contribute to our international develop-ment and will be welcome contacts.

EDAP TMS has been innovating for 38 years in the field of non-inva-sive therapies, using therapeutic ultrasound to treat multiple patholo-gies, primarily in the field of urology. Interview with Emmanuel Blanc, Director of the EDAP TMS R&D team.

Interview withEmmanuel BLANC Development Director - CTO

T. +33(0)472 153 150Cell. +33(0)620 822 421

Contact: Maude PAVAGEAUCommunication Manager

[email protected]

THERAPEUTIC ULTRASOUND

12% 16


MEDICALTEXTILES

ISO 9001:2008 and ISO 13485 certification since 2013

A multidisciplinary R&D team of 15 engineers and technicians

A technology with a wide range of possibilitiesMDB Texinov technology allows wide-ran-ging applications: dressing supports for complex wounds (burns, lesions, ulcers), textiles for implants used in the field of visceral surgery (hernia, eventration), uro-logical surgery (female and male inconti-nence, prolapse) and orthopedic surgery (ligaments).Innovation in the genesIn order to enhance its exceptional knowhow in innovation and in the design of functional technical textiles, MDB Texi-nov has a high-performance Research and Development team and an internal laboratory carrying out testing and quality controls on its products. Thanks to this or-ganization, MDB Texinov is meeting very specific requirements based on standard qualities or tailored solutions.International marketsThe MDB Texinov team is developing its unique expertise in international markets by reinforcing its various partnerships for development at international level. Ap-plied research and sharing of knowledge are key elements for growth. This is the reason why MDB Texinov is relying on the support of the i-Care Cluster and AEPI for its current and future projects.

MDB Texinov specializes in the design, development and production of warp-knitting technical textiles.The R&D team - thanks to its expertise in polymers and textile engineering - is developing solutions intended for wound care and implants.

Starting with the yarn, through beaming, knitting, decontamination and heat-setting, MDB Texinov can complete all stages of textile production.

Interview withAnne PLAT

Sales Manager / Medical markets

T. +33(0)474 974 475 Cell. +33(0)623 199 285

[email protected]

Delphine GUESNON Project Manager / Medical Business

Development

T. +33 (0)437 050 883 [email protected]

www.texinov.fr

15

Discover4 Start-ups



Why was BioparHom created?

Founded in 2008, BioparHom emerged from the realisation that there was a shor-tage of user-friendly, accurate, reliable equipment for routine clinical and sporting use. Our goal is to provide health, nutri-tion and sports professionals, together with researchers and vets, with measure-ment and diagnostic support tools that are as reliable as possible in terms of body composition data (tissues, fluid, physical condition). Constantly searching for inno-vations and refining the use of impedance measurement, BioparHom has managed to design and produce a range of diagnos-tic support systems able to measure, cal-culate and interpret all your physical pa-rameters.

What are your short-term ambitions?

We primarily target the healthcare (nephrology, oncology, geriatrics etc.) and nutrition markets (medical nutrition, dieti-cians, nutritionists, doctors etc.). The qua-lity of our products is now well established in these markets and we are continuing our research to improve our equipment (such as the option to use it lying down or standing up for elderly or obese patients) and, above all, provide more and more support for users. On this basis, we have raised funds to develop a new generation

of impedance devices that are easier to use while preserving the accuracy and ex-pertise for which we are known.

What do you hope to gain from Medica 2017?

Thanks to the regional cluster and the visi-bility it offers, we want to take advantage of our presence at Medica to find Euro-pean distributors in the nutrition and hos-pital sectors. Our products are innovative and powerful and satisfy a contemporary need. That’s why we and our new sales force are enthusiastic about this challenge!

Interview withEva CORNET

Biomedical Engineer and President

T. +33(0)951 950 818Cell. +33(0)678 645 [email protected]

www.bioparhom.com

At the cutting edge of research in the field of bioimpedance, BioparHom designs, produces and markets medical equipment for analysing body composition. Its fields of application are varied and equipment performance is very important in the diagnostic, clinical and scientific areas.

CONNECTED HEALTH

Machines in Europe

Measurements taken

Different markets

ISO 9001 ISO 13485

CE medical devices

400 180K 5


MEDICAL DEVICES

Interview withSabrina LEMRAD Sales & Marketing Director

T. +33(0)972 482 625 Cell. +33(0)669 413 [email protected]

Founded on textile expertiseNeoMedLight was born in 2014 of Bro-chier Technologies’ desire to fully exploit its Lightex® technology in the medical sector. Lightex® is based on a process for weaving optical fibres, making it possible to produce flexible, homogeneous lumi-nous surfaces. In close collaboration with Dr Anne Cortey’s team (CNRHP Trous-seau, Paris), NeoMedLight has identified immediate applications in phototherapy for neonatal jaundice.

The BiliCocoon, a major innovationAfter two years of research and develop-ment, NeoMedLight presents BiliCocoon, its first phototherapy solution designed to treat neonatal jaundice. This CE-certified system consists of a flexible sleeping bag or blanket designed as a cocoon and a unit supplying the correct wavelength of light to transform and eliminate excess biliru-bin. Designed for hospitals and home use, the system promotes skin-to-skin contact with the mother during treatment and enables breastfeeding without the need to interrupt the treatment. Effective and safe… discover this major innovation!

One year after being granted CE approval Bilicocoon is now distributed in 16 coun-tries (Germany, France, UK, Spain, Italy, the Nordic and Baltic countries, Thailand, Australia, Hong Kong…).Neomedlight is still looking to extend its distribution network worldwide.

“The official launch of the Bilicocoon sys-tem since December 2016 has been very promising with trials conducted in different countries and positive feedback received from end users whether on the ease of use, efficacy of the device but also in terms of comfort for neonates and parent-child bonding options (cocooning, cuddling and breastfeeding)”.Sabrina LEMRAD

R&D projectsNeomedlight is investing resources in new therapeutic indications involving photo-therapy such as treatments for mucositis and dermatitis, wound healing and tissue regeneration. The objective of NeoMed-Light® is to bring the innovation to all the-rapeutic fields in which it will benefit pa-tients and healthcare providers.

Strengths: • 35µW/cm2/nm - Homogenoeous

and intensive irradiance• 460 nm - Effective degradation

of Bilirubin by narrowband LEDs• 1200 cm2 - Large body surface area

covered

NeoMedLight is an innovative healthcare company with the unique technology of a light-emitting fabric made of woven optical fibres. The benefits of the Lightex® patented technology provide homogeneous distribution of light through optic fibers and thus a controlled light irradiance with a flexible, comfortable fabric which comforms to the patient’s anatomy. It is safe and easy to use! Its first innovation, the Bilicocoon system, targets neonatal jaundice for both premature and full-term babies. The blue light delivered by the Bilicocoon system throughout the fabric does not generate heat and is therefore safe for patients.

ISO 13485 certified CE Class II FDA approved Present

in 16 countries

510(K) Cleared

Distributors wanted


Interview withSylvain ZORMAN

CEO Rhizom

T. +33(0)754 555 [email protected]

www.rhizom.io

Rhizom, a start-up specialising in connecting medical devices and harvesting medical data, and TAM Télésanté, a medical manufac-turer and distributor specialising in midwife and birth centres, have partnered to give birth to the BBA-Évolution. This medical device is based on a smart and connected pulse-oximeter allowing for conti-nuous monitoring of newborns.

CONNECTEDHEALTH

CE Class IIISO 13485 certified

800,000 births a year in France

Évolution: CE marking in progress

Rhizomes from the plant world to digi-tal… what exactly is the activity of your start-up, Rhizom?

Rhizom emerged when an expert in arti-ficial intelligence, Nicolas Pernot, got to-gether with me, a doctor of engineering and researcher at Yale School of Medicine. We enable designers of medical devices to connect up and harvest the data collected by their equipment, just as the rhizome links and gives life to the elements that make up the network: the plant metaphor was ideal, don’t you think? To develop our concepts, we joined the incubator Innogex, where we work closely with CERN.

What are your recent developments, and in which field?

The market for connected objects in health is growing exponentially. Our develop-ment model is based on co-design to bring products to market quickly, drawing on the expertise of all the players involved in creating a medical device. Thanks to this model we have established a partnership with TAM Télésanté, integrating Rhizom technology with the TAM Télésanté project to create the BBA-Évolution. This product takes the form of a smart sock placed on the newborn baby’s foot, and is aimed at maternity hospitals. It is designed to pre-serve skin-to-skin contact in the delivery room. The slipper monitors the newborn, triggering an alarm if there are any anoma-lies in cardiac frequency or oxygenation.

Our technology collects data securely and enables it to be shared with healthcare players and patients. The field here is mo-nitoring newborn babies, but the applica-tions of our technology are very wide.

How will the BBA-Évolution be distri-buted?

The BBA-Évolution will be sold directly to maternity units. It will be distributed in France exclusively by NATech, the French leader in medical equipment distribution for maternity hospitals.

What do you hope to gain from Medica 2017?

The i-Care Cluster gives us definite visi-bility and strong momentum by bringing together unique skill sets. Our main ob-jective will be to promote BBA-Evolution, but we will also aim to make contact with designers and manufacturers of medical devices who want to innovate and give their products the essential dimension of connectivity to a cloud!

BBA


Interview withWilliam WIECEK Chairman

T. +33(0)477 364 335Cell. +33(0)643 696 [email protected]

After just a few years of research and development, SETMI Médical is targeting a position as the benchmark manufacturer for the treat-ment of thoracic pathologies. Pneumothorax brush, vacuum bell for pectus excavatum, compression brace for pectus carinatum and prosthetic ribs… these innovative, simple-to-use, effective solutions are finding their place in the operating theatre and in our therapeutic practice. William Wiecek presents SETMI’s activities.

MEDICAL DEVICES

3

3 families of patents registered - France,

Europe, World

ISO 13485 certified by LNE/GMED

ThoPa-Brush® and ThoPEC®

brought to market in 2017

SETMI was created in response to unmet needs in thoracic surgery and patholo-gy…Yes, our start-up emerged from needs identified by an expert thoracic surgeon, Professor Olivier Tiffet at CHU Saint-Étienne. Bringing together specialists from complementary scientific and indus-trial fields, Olivier Tiffet founded SETMI in 2012 and began to develop his first me-dical devices with his team. These were the ThoPA-Brush® (class IIA) for trea-ting spontaneous pneumothorax and the ThoPEC® for pectus carinatum; following the necessary testing and certification, the products were brought to market in 2017. The team is currently developing further equipment, such as the T-Bell®, a vacuum bell for pectus excavatum, and the TOS-Can®, a prosthetic rib.

What makes your products different or innovative?Our products, and particularly the Tho-Pa-Brush®, are breakthrough products. The ThoPa-Brush® is a single-use device introduced using a trocar (thoracoscopy). It is used to treat pneumothorax via mecha-nical pleural abrasion. Surgical innovation, safety and standardisation for effective, long-lasting treatment… and real benefits in terms of patient comfort. In the same spirit, the ThoPEC® and T-Bell® approach and treat pathology differently. These treatments for sternums deformed towar-ds the interior or exterior of the rib cage act through external aspiration or pressure. They are proven techniques and we call them compassionate products.This exhibition is a “first” for SETMI: what do you expect from it?We are currently marketing our products in France and Switzerland. This international show is a great opportunity for SETMI, be-cause we benefit from high visibility under the banner of the Region and the i-Care Cluster. It will be a chance to form contacts and partnerships with distributors in Eu-rope and worldwide. Our innovative solu-tions for thoracic surgery and pathology are easy to localise and export!

Saint Etienne Thoracic Medical Innovation


Contact us!

Nathalie [email protected]

Adriana [email protected]

We have supported them to set up in Lyon

> SCIENION

> COSMED

> BAXTER

> FRESENIUS

> NOVA DFL

> NEUROSOFT

Lyon Area A Comprehensive Medtech Value ChainTo attract foreign and direct investments, we are mobilizing our network of active players and experts in Health sector.

A wide range of skills awaits for you: R&D, testing, manufacturing, subcontracting, distribution, regulatory consultants, clinical CROs, etc.

Single-use materials

Electro-medical devices / dialyses

Sub-contractors

Implantable devices & prostheses

Medical textiles

You are interested in setting up activities in our Healthtech territory?

Invest in Lyon agency provides the support you need to help you succeed.


Joëlle SEUX Deputy Director

T. +33 (0)476 709 722Cell. +33 (0)607 799 [email protected]

Adeline CICCOLELLA Head of Inward Investment, Medtechs and Life Sciences

T. +33 (0)457 384 988

[email protected]

Need help to develop your business in France?

We offer customized solutions: take advantage of our expertise!

• BUSINESS & SECTOR INFORMATION

• SCHEDULING OF VISITS & MEETINGS

• REAL ESTATE PROPOSALS & VISITS

• ASSISTANCE IN OPENING & OPERATING YOUR FRENCH ORGANIZATION

• RESEARCH ON FUNDING

• CONNECTION WITH THE LOCAL ECOSYSTEM

• HR & RECRUITING SUPPORT

©ES

RF-A

EPI

The only regionin France with 4 university hospitals

European Inventor Award (2016)Breakthrough Prize in Life Sciences (2015)

13 Grenoble projects rewarded at the World Competition of Innovation in 2016

Academic research teams

200

Grenoble projects rewarded at the World Competition of Innovation in 2016

€Over 140 medical technology

companies, 1/4 foreign-owned, employing ¾ of the sector’s workforce

€

Students

9,000

Jobs

10,900

Grenoble-Isère, France: Europe’s Medtech valley, where you will find sites operated by BD, Cognizant, GE, Illumina, Medtronic, Roche Diagnostics and Capgemini among others, with specific high-tech skills such as minimally invasive technologies, medical textiles, biomaterials, medical imaging, connected health, drug delivery systems, surgical navigation…


Medi’Nov Connection 2018European meetings dedicated to the design and manufacturing of medical equipments and devices.

www.medinov-connection.com

INNOVATION PITCHES Led by LyonBiopole, the Innovation Pitches highlighted 8 innovative companies through flash presentations. At the end of the pitch session, the audience, composed of industrial companies active in the medical field, had the opportunity to vote for the most innovative company. And the winner is ... MICROLIGHT 3D.

Medi’Nov Connection 2018WTC Congress Center GRENOBLE (France)

21th & 22th March 2018

B2B & EXHIBITORS MEETINGS In 2017, more than 90 exhibitors (SME and start-ups) were expected to present their innovative technology and know-know to medical equipment manufacturers, through more than 3,450 B2B meetings.

THEMATIC TECHNOLOGY CONFERENCES With a duration of 30 minutes each, these conferences present technological innovations or deal with topics in relation to medical devices and equipment market evolution.

In 2017, conferences focused on 3 main themes: innovation and technology transfer, regulations and connected health.

A SHOWROOM AREA In 2017, Medi’Nov offered the opportunity to access a showroom dealing with innovative topics for the medical industry.

This area allowed visitors to discover some applications related to the design and manufacturing of medical devices and equipment.

ROUND TABLES In 2017, two sessions were organized:

“Standard and regulation news about medical devices”, led by the i-Care Cluster.

“Growth of health technology companies: Strategy and return on operative experience”, led by MEDICALPS.

21TH & 22TH MARCH 2018 GRENOBLE (FRANCE)

MEDI’NOVC O N N E C T I O N

HEALTH TECHNOLOGY AUVERGNE-RHÔNE-ALPES CLUSTER

321, Avenue Jean Jaurès 69007 Lyon • FranceT. +33 (0)472 727 060 [email protected]

@i_carecluster

www.i-carecluster.org

Supported by:

© M

ich

el P

érès

/Rég

ion

Au

verg

ne-

Rhô

ne-

Alp

es &

iSto

ck p

ho

tos

• D

esig

n : arte

nium

® •

10/

2017

• A

ll rig

hts

rese

rved

Saint Etienne Thoracic Medical Innovation


an expanding healthtech ecosystem -...

Documents